Your browser doesn't support javascript.
loading
Four-Way Crossover Phase 1 Thorough QT Study to Assess Cardiac Safety of Domperidone and Consideration for Design and Conduct of QT/QTc Study in China.
Wang, Fangfang; Nie, Jing; Yang, Li; Yang, Zhenhua; Xu, Lin; Wang, Liqun; Liao, Huimin; Li, Mengyu; Wang, Ping; Li, Gailing; Li, Haiyan.
Afiliação
  • Wang F; Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital, Beijing, China.
  • Nie J; NHC Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Peking University Third Hospital, Beijing, China.
  • Yang L; Key Laboratory of Molecular Cardiovascular Science, Ministry of Education, Peking University Third Hospital, Beijing, China.
  • Yang Z; Beijing Key Laboratory of Cardiovascular Receptors Research, Peking University Third Hospital, Beijing, China.
  • Xu L; Janssen China R&D, Beijing, China.
  • Wang L; Department of Pharmacy, Peking University Third Hospital, Beijing, China.
  • Liao H; Drug Clinical Trial Center, Peking University Third Hospital, Beijing, China.
  • Li M; Drug Clinical Trial Center, Peking University Third Hospital, Beijing, China.
  • Wang P; Janssen China R&D, Beijing, China.
  • Li G; Janssen China R&D, Shanghai, China.
  • Li H; OTC Medical Affairs, Xian Janssen Pharmaceutical Ltd., Beijing, China.
Clin Pharmacol Drug Dev ; 11(6): 734-743, 2022 06.
Article em En | MEDLINE | ID: mdl-35157791
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Síndrome do QT Longo / Domperidona Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Revista: Clin Pharmacol Drug Dev Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Síndrome do QT Longo / Domperidona Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Revista: Clin Pharmacol Drug Dev Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China